Stokkel, Laura E. and Stokkel, Marcel P. M. and Donswijk, Maarten L. and Lahaye, Max J. and Bekers, Elise M. and van Rhijn, Bas W. G. and Mertens, Laura S. (2021) The Diagnostic Value of FDG-PET/CT for Urachal Cancer. CLINICAL GENITOURINARY CANCER, 19 (5). pp. 373-380. ISSN 1558-7673, 1938-0682
Full text not available from this repository. (Request a copy)Abstract
Urachal cancer is a very rare malignancy. There is no consensus on the optimal form of staging for this disease. In this study, we evaluated FDG-PET/CT for staging urachal cancer in 40 patients. We found that most of the urachal tumors can be visualized on FDG-PET/CT but that it seems to add little additional staging information compared with standard CT. Background: Urachal carcinoma (UrC) is a rare malignancy that often presents at an advanced stage with metastases in up to a quarter of patients. There is no consensus on the optimal form of staging for patients with UrC. In the present study, we evaluated the diagnostic value of 18 F-fluorodeoxyglucose-positron emitted tomography/computed tomography (FDG-PET/CT) for UrC. Patients and Methods: We evaluated 40 consecutive patients who were staged for urachal cancer between 2010 and 2020. They underwent a total of 62 FDG-PET/CTs (40 for primary staging, and 22 during follow-up), which were compared with standard-of-care contrast-enhanced CT (CECT). The metabolic detection of primary tumors, lymph node metastases (LNMs), peritoneal metastases (PMs), distant metastases (DMs), and local recurrence by FDG-PET/CT was evaluated. Sensitivit y and specificit y were calculated compared with CECT. Histopathology or follow-up imaging was the reference standard. Results: Of all 40 patients, 33 patients (83%) had urachal adenocarcinoma-26 (65%) with a mucinous component and 7 (17%) with invasive urothelial carcinoma. All local UrC tumors could be visualized on CT, and 80% showed increased FDG uptake. At initial staging, FDG-PET/CT detected FDG-avid LNMs, PMs, and DMs in 50%, 17%, and 25% of patients, respectively. These metastases were also visualized on CECT. During follow up, FDG-PET/CT revealed FDG-avid local recurrences that were not seen on CT in two out of eight patients (25%). Conclusion: The present study demonstrates that most UrC can be visualized on FDG-PET/CT. At initial diagnosis, FDG-PET/CT does not seem to yield additional information compared with CECT; however, FDG-PET/CT may be helpful during follow-up. This is a small study, and the findings should be corroborated with larger series. (C) 2021 Elsevier Inc. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; MUCINOUS ADENOCARCINOMA; Urachus; Staging; Carcinoma; Imaging; Metastasis |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Sep 2022 08:22 |
| Last Modified: | 14 Sep 2022 08:22 |
| URI: | https://pred.uni-regensburg.de/id/eprint/47405 |
Actions (login required)
 |
View Item |
